Sensitization Prevention: Foundational Strategy for Severe Cases
Rather than treating ME/CFS symptomatically in isolation, this protocol addresses the critical observation that severe disease represents a cascade of progressive sensitization (MCMC Research 2024). Each new system involvement, infection, or crash deepens neuroinflammatory priming and reduces tolerance for future perturbations. Prevention of further sensitization is the primary therapeutic goal for severe patients.
Anti-Neuroinflammatory Foundation
Initiate immediately:
Low-dose naltrexone (LDN): Titrate from 0.5 mg to 4.5 mg over 4–6 weeks at bedtime. Monitor for psychiatric effects (mood destabilization, emotional lability) as microglial downregulation paradoxically can unmask underlying mood pathology. Benefits include glial cell downregulation and endogenous opioid restoration (NIH ME/CFS Research Roadmap Working Group 2024).
Palmitoylethanolamide (PEA): 1200 mg daily (micronized form only; standard PEA poorly absorbed). PPAR-\(\alpha\) agonism provides sustained anti-inflammatory and mast cell stabilizing effects (Viña et al. 2025).
Omega-3 polyunsaturated fatty acids: 3 g EPA/DHA daily (split into meals for tolerability). Supports neuronal membrane fluidity and endogenous anti-inflammatory mediator production (MCMC Research 2024).
Strict Pacing with Objective Monitoring
Sensitization amplification occurs through repeated crashes and energy envelope violations. Prevent this:
Continuous heart rate monitoring: Wear device 24/7; learn individual anaerobic threshold (AT). Maintain activities strictly below AT. For bedbound patients, even small movements (self-care, family interaction) must be monitored.
Zero-crash goal: The protocol explicitly aims for zero crashes during the sensitization prevention window (ideally 3–6 months). Each crash resets progress by consuming recovery reserve and amplifying sensitization.
Anticipatory pacing: Reduce activity before feeling symptomatic. Severe patients must learn to pace preemptively rather than reactively.
Sleep Architecture Optimization
Sleep loss is a primary driver of glymphatic impairment and sustained neuroinflammation (MCMC Research 2024). This is non-negotiable:
Sleep study mandatory: Identify and treat sleep apnea, periodic limb movements, or REM behavior disorder.
Pharmaceutical sleep support: Melatonin (1–3 mg) or dual orexin receptor antagonist (suvorexant 5–10 mg) prioritized for slow-wave sleep enhancement. Target: 7–8 hours with \(\geq\) 85% sleep efficiency.
Positional optimization: Side sleeping (particularly left side) optimizes glymphatic clearance geometry. Avoid supine positioning if possible.
Infection Barrier Maintenance
Each infection triggers neuroinflammatory amplification and can produce permanent baseline functional decline. Prevention is critical:
Prophylactic antivirals: N95/FFP2 masking in any crowded setting. Consider prophylactic famciclovir (250 mg daily) or valacyclovir (500 mg daily) during winter/high-transmission seasons, especially if frequent reactivation is documented.
First-symptom protocol: At first symptom of infection (sore throat, malaise, fever), immediately begin antiviral therapy (high-dose valacyclovir 1000 mg QID or IV acyclovir if tolerated) and rest protocol. Early treatment reduces infectious-trigger damage magnitude (NIH ME/CFS Research Roadmap Working Group 2024).
Immunization strategy: Live vaccines absolutely contraindicated. Inactivated vaccines acceptable only during periods of clinical stability; discuss timing with knowledgeable provider.
Lactate Shuttle Cofactor Optimization
The astrocyte-neuron lactate shuttle (ANLS) is estimated to provide 30–50% of neuronal ATP (Pellerin and Magistretti 1994). The hypothesis that ANLS dysfunction may cause CNS-specific energy failure while peripheral tissues remain intact is discussed in Chapter Selective Energy Dysfunction Hypothesis. If this hypothesis is correct, supporting the lactate shuttle may enhance CNS energy availability.
Components:
Thiamine (Vitamin B1): 100–300 mg daily
- Dose: Start 100 mg daily, titrate to 200–300 mg if tolerated
- Rationale: Thiamine is essential for pyruvate dehydrogenase complex, which converts pyruvate to acetyl-CoA for CNS energy production. Dosing exceeds RDA (1.1–1.2 mg) but aligns with therapeutic B1 dosing for neurological conditions.
- Timing: Morning with breakfast
- Safety: Very safe; water-soluble, excess excreted. No upper limit established.
MCT Oil (Medium-Chain Triglycerides): Titrate from 1 tsp bedtime to 1 tbsp TID
- Rationale: MCTs bypass long-chain fatty acid metabolism and provide rapid ketone production, providing alternative CNS fuel when lactate shuttle is impaired
- Protocol: Start 1 tsp (5 mL = 5 g) at bedtime. After 1 week, add 1 tsp with breakfast. After 2 weeks, add 1 tsp with lunch. Target: 1 tbsp TID (15 mL = 15 g) if tolerated.
- GI monitoring: MCT can cause GI upset (cramping, diarrhea); titrate slowly. Take with food.
- Evidence level: Plausible (MCT metabolism established; ME/CFS-specific efficacy unproven)
Exogenous Ketones (Optional): Consider if MCT insufficient
- Ketone bodies: Provide direct neuronal fuel independent of glucose-lactate pathway
- Options: Ketone salts (sodium/calcium beta-hydroxybutyrate) or MCT oil-derived ketones
- Dose: 5–15 g daily divided doses (follow product guidelines)
- Evidence level: Speculative (ketones show promise in neurological conditions; ME/CFS efficacy not established)
Evidence level: Plausible (ANLS dysfunction mechanistically relevant; clinical validation pending)
Expected outcomes: Improved cognitive clarity, reduced fatigue, better sustained attention. Timeline: 2–4 weeks for noticeable effect.
Metabolic Protection and Monitoring
Severe ME/CFS is characterized by hypometabolic state and impaired glucose handling (MCMC Research 2024). Additional metabolic stress amplifies sensitization:
Quarterly HbA1c monitoring: If trending upward (especially if approaching prediabetes range \(\geq\) 5.7%), initiate metformin 500 mg daily (titrate to tolerance). Metabolic dysregulation intensifies neuroinflammation and reduces treatment efficacy (MCMC Research 2024).
Caloric adequacy: Severe patients often restrict intake due to GI symptoms or cognitive dysfunction. Ensure minimum caloric support (target: 1500–1800 kcal daily). Undereating amplifies mitochondrial stress and neuroinflammation.
Electrolyte homeostasis: Monitor sodium/potassium; replace as needed. Many severe patients become sodium-depleted from reduced oral intake; careful repletion supports autonomic stability.
Rationale and Duration
The sensitization-prevention protocol targets the documented cascade in which neuroinflammatory priming lowers the threshold for all symptom exacerbations (see Chapter Selective Energy Dysfunction Hypothesis). By stabilizing this foundation, subsequent treatments for individual systems (immune reconstitution, cognitive rehabilitation, autonomic retraining) have higher probability of efficacy.
Duration: Maintain this protocol for minimum 3–6 months as foundation. Once sensitization is arrested (no new crashes, stable baseline), can add additional interventions from Section Medium-Term Recovery Strategies (Weeks to Months).